Patents by Inventor Hilde Lavreysen

Hilde Lavreysen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
    Patent number: 11369606
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 28, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20220143141
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 10, 2021
    Publication date: May 12, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20220047593
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 17, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
    Patent number: 11103506
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 31, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20200138813
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20200138814
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Inventors: Brian D. KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
    Patent number: 10537573
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: January 21, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
  • 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
    Patent number: 9708315
    Abstract: The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: July 18, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Marc André Ceusters, Hilde Lavreysen
  • COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE
    Publication number: 20160367554
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Application
    Filed: January 20, 2015
    Publication date: December 22, 2016
    Inventors: Brian D KLEIN, Hilde LAVREYSEN, Stefan Maria, Christiaan PYPE, Roy E. TWYMAN, Nancy Eulalie, Sylvain VAN OSSELAER, H. Steven WHITE, Marc André CEUSTERS, José Maria CID-NÚÑEZ, Andrés Avelino TRABANCO-SUÁREZ, Roger Francis BONE
  • 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
    Publication number: 20160194318
    Abstract: The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.
    Type: Application
    Filed: September 3, 2014
    Publication date: July 7, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Marc André Ceusters, Hilde Lavreysen
  • Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
    Patent number: 7517517
    Abstract: The present invention is concerned with radiolabelled quinoline and quinolinone derivatives according Formula (I-A)* or (I-B)* showing metabotropic glutamate receptor antagonistic activity, in particular mGlu1 receptor activity, and their preparation; it further relates to compositions comprising them, as well as their use for marking and identifying metabotropic glutamate receptor sites and for imaging an organ.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: April 14, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Anne Simone Josephine Lesage, François Paul Bischoff, Cornelus Gerardus Maria Janssen, Hilde Lavreysen
  • Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
    Publication number: 20060083676
    Abstract: The present invention is concerned with radiolabelled quinoline and quinolinone derivatives according Formula (I-A)* or (I-B)* showing metabotropic glutamate receptor antagonistic activity, in particular mGlu1 receptor activity, and their preparation; it further relates to compositions comprising them, as well as their use for marking and identifying metabotropic glutamate receptor sites and for imaging an organ.
    Type: Application
    Filed: March 26, 2003
    Publication date: April 20, 2006
    Inventors: Anne Lesage, Francois Bischoff, Cornelus Janssen, Hilde Lavreysen